Polaris Announces Results of a Phase 2 Trial of ADI-PEG 20 in Relapsed/Refractory or Poor-risk Acute Myeloid Leukemia

SAN DIEGO, September 12, 2017 – Polaris Group announced today that its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) demonstrated a good safety profile and an efficacy signal as monotherapy in a phase 2 trial in relapsed/refractory or poor-risk acute myeloid leukemia (AML) patients, as reported in the journal Scientific…

Polaris Group Announces Treatment of First Patient in Phase 2/3 Study of ADI-PEG 20 Plus Cisplatin and Pemetrexed in Malignant Pleural Mesothelioma

SAN DIEGO, August 2, 2017 – Polaris Group announced today that the first patient has been dosed in its randomized, placebo-controlled, double blind phase 2/3 trial (ATOMIC-meso) in malignant pleural mesothelioma (MPM) patients. Patients will be randomized to receive ADI-PEG 20 (pegylated arginine deiminase) or placebo in combination with pemetrexed…

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Tumors

SAN DIEGO, July 14, 2017 – Polaris Group announced today that the first patient has been dosed in its phase 1 trial of ADI-PEG 20 in combination with pembrolizumab for the treatment of advanced solid tumors. In addition to a global phase 2/3 trial in malignant plural mesothelioma featuring ADI-PEG…

Polaris Lead Therapeutic ADI-PEG 20 in Combination with First Line Chemotherapy Is Active in Argininosuccinate Synthetase Deficient Mesothelioma

SAN DIEGO, June 5, 2017 – Polaris Group announced today that its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) in combination with pemetrexed and cisplatin (ADIPemCis) is active in argininosuccinate synthetase (ASS1) deficient malignant pleural mesothelioma (MPM), including non-epithelioid MPM, which carries an unfavorable prognosis and historically responds poorly to…

Polaris Provides Early Evidence of Response to Arginine Depletion by ADI-PEG 20 in Argininosuccinate Synthetase Deficient Thoracic Tumors

SAN DIEGO, April 20, 2017 – Polaris Group announced today that its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) in combination with pemetrexed and cisplatin (ADIPemCis) demonstrated a good safety profile and a strong efficacy signal in argininosuccinate synthetase (ASS1) deficient malignant pleural mesothelioma (MPM) and non-small cell lung carcinoma…

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 Plus Cytarabine in Older Patients with Acute Myeloid Leukemia

SAN DIEGO, January 20, 2017 – Polaris Group announced today that the first patient has been dosed in its phase 1 trial of ADI-PEG 20 in combination with low-dose cytarabine for the treatment of acute myeloid leukemia (AML) in older patients. In addition to a global phase 2/3 study in…

ADI-PEG 20 plus FOLFOX Shows Robust Anti-tumor Activity in Advanced Hepatocellular Carcinoma

SAN DIEGO, January 19, 2017 – Polaris Group announced today results from an ongoing phase 1b study conducted at Memorial Sloan Kettering Cancer Center that tests combining ADI-PEG 20 with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in patients with advanced hepatocellular carcinoma (HCC) and other gastrointestinal malignancies. The results will be presented at the 2017 Gastrointestinal Cancers Symposium in San Francisco.

ADI-PEG 20 Radio-sensitizes Pancreatic Cancer Cells by Amplifying Early Endoplasmic Reticulum Stress

SAN DIEGO, Nov. 8, 2016 /PRNewswire/ — Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, can selectively enhance the effect of radiation in argininosuccinate synthetase (ASS1) deficient pancreatic tumors according to results presented by researchers from MD Anderson Cancer Center at the annual meeting of the American Society for Radiation Oncology (ASTRO).

ADI-PEG 20 Can Boost Anti-Tumor Immune Surveillance

SAN DIEGO, Oct. 24, 2016 /PRNewswire/ — Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, can boost anti-tumor immune surveillance according to research presented by Polaris at the 2016 American Association for Cancer Research Tumor Immunology and Immunotherapy conference in Boston.

Polaris Group Reports Phase III Study Results of ADI-PEG 20 plus Best Supportive Care in Advanced Hepatocellular Carcinoma

CHICAGO, June 6, 2016 /PRNewswire/ — Polaris Group announced today that the phase III study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma (HCC) did not meet its primary endpoint of demonstrating overall survival (OS) benefits. Median OS was 7.8 months for ADI-PEG 20 vs. 7.4 months for placebo (p = 0.884, HR=1.022 [95% CI: 0.847, 1.233]).